Robert-Bosch-Krankenhaus

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification (2023) Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, et al. Journal article Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience (2023) Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Journal article Einfluss des Klimawandels auf Infektionskrankheiten in der Nephrologie (2023) Kraft L, Schmidt-Chanasit J, Paul G, Amann KU, Latus J Journal article, Review article A multi-sensor wearable system for the assessment of diseased gait in real-world conditions (2023) Salis F, Bertuletti S, Bonci T, Caruso M, Scott K, Alcock L, Buckley E, et al. Journal article Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 (2023) Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, et al. Journal article Reference equations for harmonizing gait speed results of different test protocols in community-dwelling older adults (2022) Lindemann U, Krumpoch S, Freiberger E, Klenk J Journal article Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort (2022) Freise NF, Gliga S, Fischer J, Lübke N, Lutterbeck M, Schöler M, Bölke E, et al. Journal article Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST) (2022) Sockel K, Frank S, Neu A, Ditschkowski M, Hilgendorf I, Goeckenjan M, Stoelzel F, et al. Conference contribution Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) Roellig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Haenel M, et al. Conference contribution Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma (2022) Straka C, Schaefer-Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, Kroenke J, et al. Conference contribution